WinRho SDF (Rho(D) Immune Globulin Intravenous (Human): Risk of Intravascular Hemolysis
admin | Mar 17, 2010
Cases of intravascular hemolysis and its complications have been reported in patients treated for immune thrombocytopenic purpura with WinRho.
Related Posts:
- GammaGard Liquid, Immune Globulin Intravenous (Human)
- Velcade (bortezomib): Starting Dose Adjustments for Patients with Hepatic Impairment
- Velcade (bortezomib): Starting Dose Adjustments for Patients with Hepatic Impairment
- Promacta (eltrombopag): Portal Venous System Thromboses in Study of Patients With Chronic Liver Disease
- Weighing Parents’ Preferences And Risk Factors When Choosing Vaginal Birth After Cesarean (VBAC) Or Plan A Repeat Cesarean
Filed Under: Dangerous Drugs
